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Abstract: Objectives: Lately, many countries have restricted or even banned transfat, and palm oil
has become a preferred replacement for food manufacturers. Whether palm oil is potentially an
unhealthy food mainly due to its high content of saturated Palmitic Acid (PA) is a matter of debate.
The aim of this study was to test whether qualitative aspects of diet such as levels of PA and the fat
source are risk factors for Metabolic Syndrome (MS) and Metabolic Associated Fatty Liver Disease
(MAFLD). Methods: C57BL/6 male mice were fed for 14 weeks with three types of Western diet (WD):
1. LP-WD—low concentration of PA (main fat source—corn and soybean oils); 2. HP-WD—high
concentration of PA (main fat source—palm oil); 3. HP-Trans-WD—high concentration of PA (mainly
transfat). Results: All types of WD caused weight gain, adipocyte enlargement, hepatomegaly, lipid
metabolism alterations, and steatohepatitis. Feeding with HP diets led to more prominent obesity,
hypercholesterolemia, stronger hepatic injury, and fibrosis. Only the feeding with HP-Trans-WD
resulted in glucose intolerance and elevation of serum transaminases. Brief withdrawal of WDs
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reversed MS and signs of MAFLD. However, mild hepatic inflammation was still detectable in HP
groups. Conclusions: HP and HP-Trans-WD play a crucial role in the genesis of MS and MAFLD.
Keywords: obesity; metabolic associated fatty liver disease (MAFLD); steatohepatitis; fibrosis;
palmitic acid (PA)
1. Introduction
Metabolic Associated Fatty Liver Disease (MAFLD) is characterized by the presence
of hepatic steatosis in addition to any of the following three criteria: overweight or obesity,
presence of Type 2 Diabetes Mellitus (T2DM) or evidence of metabolic dysregulation [1].
Since its initial description [2] in 1980, the incidence and prevalence of MAFLD has in-
creased dramatically, in parallel with the global epidemic of obesity. Today, it is the most
widespread liver disease in human history, affecting about a quarter of the global popula-
tion. In European countries, 25% of individuals aged ≥15 years experienced MAFLD in
2015 [3]. Alongside the progressive liver damage, MAFLD is becoming an established risk
factor for the leading causes of death and disability, namely cardiovascular disease and
cancer. Despite these already staggering facts, the MAFLD burden is expected to grow in
the coming decades, compromising individual health and health-care systems and causing
substantial economic and well-being losses [4,5].
MAFLD is often referred to as a self-inflicted disease, implying the influence of
personal behavioral and dietary choices. However, the impact of the surrounding “fast
and processed food” obesogenic environment on the choices of children and adults should
not be neglected [1]. Processed or ready-to-consume food products are characteristically
energy-dense, fatty, sugary or salty. At the same time, they are hyper-palatable, cheap and
attractive, therefore highly dominant, and they comprise the majority of the total energy
intake among young adults currently [6,7].
The food industry and especially the fast-food industry, extensively uses the types of
lipids with long shelf life that are easy and inexpensive to produce [8]. Processing natural
liquid vegetable oils, by adding hydrogen, modifies their texture from liquid to solid forms
and results in the development of transfats (or partially hydrogenated fats). Trans Fatty
Acids (FA) give food a desirable taste and texture. The main examples of industrial Trans
FA are margarines, commercially baked products, deep-fried fast foods, packaged snack
foods and other prepared food [9]. According to the U.S. Food and Drug Administration
(FDA), in 1994–1996 we consumed about 5.6 g of transfat per day [10].
In the early 1990s, researchers began to identify the adverse health effects and re-
ported that intake of Trans FA increased the risk of coronary heart disease by altering the
ratio between Low-Density Lipoprotein (LDL) cholesterol and the “good” High-Density
Lipoprotein (HDL) cholesterol [11].
Increased consumer awareness of the health implications of Trans FA resulted in local
and state efforts to limit or ban their use [9].
“Anti transfat” measures introduced by governments accelerate the use of an accessi-
ble alternative—palm oil, obtained from the fruit of the palm tree (Elaeis guineensis). Palm
oil is abundant, low-cost and chemically stable. Currently, it is the most widely produced
edible vegetable oil in the world [12]. Palm oil is rich in saturated FAs, especially Palmitic
Acid (PA), unlike most of the vegetable oils, which are rich in unsaturated fat. For this
reason, palm oil is semisolid at room temperature, making it suitable for the formulation of
processed food [13].
Recently, the impact of palm-oil consumption on the heart, especially in the develop-
ment of coronary artery disease, was a matter of considerable debate. The main argument
against the use of palm oil is the fact that it contains saturated PA, which may case elevation
of total cholesterol and LDL levels [14].
Currently, transfat and PA consumption remain a major source of concern within
health policies regarding the reduction of cardiovascular and metabolic-disease risk [15,16].
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However, evidence of the consequences of transfat and PA consumption in the development
of MAFLD is scarce and even controversial. In the present study, we investigated whether
this type of FA could have an impact on MAFLD progression.
2. Materials and Methods
2.1. Animal Experimentation
All animal procedures were performed according to Spanish legal requirements and
animal protection law, and were approved by the authority of environment conservation
and consumer protection of the Regional Government of Madrid (PROEX210/18, 15 June
2018). All animals were maintained in the Animal Facility at the Faculty of Biology,
Complutense University Madrid, in a temperature-controlled room with 12-h light/dark
cycle with ad libitum feeding condition, according to the guidelines of the Federation for
Laboratory Animal Science Associations (FELASA).
We randomly distributed 10-week C57BL/6J male mice into 4 groups with a sample
size of 7 to 9 animals per group.
Control (CTRL) group was fed with chow diet and normal water. Three treated groups
received different types of Western Diet (WD) (Supporting Tables S1–S3) and sweetened
drinking water containing 6.75% D-glucose (Sigma-Aldrich, St. Louis, MO, USA). For
the withdrawal study, we established a model in which mice were exposed to WD and
sweetened drinking water for 14 weeks, followed by 20 days of chow diet and normal
water. The corresponding controls received chow diet and normal water for 17 weeks.
2.2. Supplementary Material and Methods
Please see Supplementary online material and Supporting Tables S4–S7 for further in-
formation regarding material and methods on Animal Experimentation, Glucose Tolerance
Test (GTT), Histological analysis, Immunofluorescence (IF) and Immunohistochemistry
(IHC) staining, Image analysis, RNA isolation and RT-qPCR, Western blot, and Lipid
extraction and quantification.
2.3. Statistical Analysis
Data were expressed as mean ± SD. GraphPad Prism version 8.0 (https://www.
graphpad.com/scientific-software/prism/), accessed 27 December 2018 (San Diego, CA,
USA) was used for statistical analysis and graph design. Statistical significance was
determined by one-way analysis of variance ANOVA, followed by a Tukey post hoc test.
One-way paired ANOVA followed by Bonferroni’s post hoc test was used to evaluate the
differences between feeding groups. Significant differences are denoted by * for p < 0.05,
** p < 0.01, *** p < 0.001; **** p < 0.0001.
3. Results
3.1. Western Diet (WD) Is Associated with the Development of Obesity and Metabolic
Syndrome (MS)
Ten week-old C57BL/6J male mice were fed with three different WDs and sweetened
water for 14 weeks. The three types of WD had a similar content of fat (40%), fructose
(22%) and cholesterol (2%) (Supporting Tables S1 and S2). However, the origin of fat and
the level of PA was greatly different between the groups. In group 1, the level of PA was
low (LP-WD), and the corn and soybean oils were the main source of fat. In group 2, the
level of PA was high (HP-WD) due to the palm oil added to the formula. In group 3, the
level of PA was also high (HP-Trans-WD), but the transfats were the main source of the fat
(Supporting Tables S1–S3). Glucose was added to the drinking water in order to potentiate
fructose absorption from the diet [17]. Mice fed with the control chow diet and filtered tap
water were used as controls.
Body Weight (BW) steadily increased in all treated groups during the experimental
period. Nevertheless, as shown in (Figure 1A,B), throughout the 14-week period the mice
fed with LP-WD, on average, gained less weight compared to HP-WD and HP-Trans-WD.
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Figure 1. Metabolic profile of mice treated with different types of WD and control (CTRL) group. 
(A) Left: BW curve during the feeding period. Right: Area under the BW curve (arbitrary units) after 
14 weeks. (B) End point body weight after 14 weeks of feeding (n = 7–9). (C) Upper: eWAT weight 
(g) (n = 7–9). Lower: eWAT weight–to-BW ratio (%) (n = 7–9). (D) Representative eWAT H and E. 
Asterisks indicate CLS. Scale bar = 100 μm (n = 4–5). (E) Left: Basal glucose levels in blood after 12 h 
of fasting (n = 3–5). Right: GTT curve after 14 weeks feeding. (F) Levels of cholesterol in serum (n = 
6–8). * for p < 0.05, ** p < 0.01, *** p < 0.001; **** p < 0.0001. 
3.2. WD Consumption Triggered Hepatomegaly 
Obesity, hypercholesterolemia and glucose intolerance are the main features of MS 
and are closely associated with the progression and severity of MAFLD [19]. Anato-
mopathological examination of livers revealed that the hepatic parenchyma of all mice fed 
with WD was significantly enlarged and pale yellow in color. Accordingly, the liver mass 
and hepatosomatic ratio were increased in all treated groups compared with CTRL mice 
(Figure 2A). 
Figure 1. Metabolic profile of mice treated with different types of WD and control (CTRL) group. (A) Left: BW curve during
the feeding period. Right: Area under the BW curve (arbitrary units) after 14 weeks. (B) End point body weight after
14 weeks of feeding (n = 7–9). (C) Upper: eWAT weight (g) (n = 7–9). Lower: eWAT weight–to-BW ratio (%) (n = 7–9).
(D) Representative eWAT H and E. sterisks indicate CLS. Scale bar = 100 µm (n = 4–5). (E) Left: Basal glucose levels in
blood after 12 h of fasting (n = 3–5). Right: GTT curve after 14 weeks feeding. (F) Levels of cholesterol in serum (n = 6–8).
* for p < 0.05, ** p < 0.01, *** p < 0.001; **** p < 0.0001.
Obesity is associated with significant changes in White Adipose Tissue (WAT), which
has profound systemic and hepatic consequences [18]. Mice fed with all types of WD
diet accumulated epididymal WAT (eWAT) and had higher visceral fat mass compared
to control animals (Figure 1C, Supplementary Figure S1A). The administration of WDs
also led to hypertrophy and increase of adipocyte size up to 80% after 14 weeks of WD
feeding (Figure 1D, Supplementary Figure S1B). Additionally, Crown-Like Structures (CLS)
formed by macrophages aggregated around dying adipocytes were observed in all WD
groups (Figure 1D).
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Basal glucose levels after 12 h of fasting, did not increase in all WD treated groups
compared with CTRL (Figure 1E, left panel). However, a Glucose Tolerance Test (GTT)
revealed significantly impaired glucose tolerance in mice fed a HP-Trans-WD (Figure 1E,
right panel, Supplementary Figure S1C).
Finally, the serum level of total cholesterol was significantly higher in HP-WD and
HP-Trans-WD fed animals compared with LP-WD and CTRL groups (Figure 1F).
3.2. WD Consumption Triggered Hepatomegaly
Obesity, hypercholesterolemia and glucose intolerance are the main features of MS
and are closely associated with the progression and severity of MAFLD [19]. Anato-
mopathological examination of livers revealed that the hepatic parenchyma of all mice
fed with WD was significantly enlarged and pale yellow in color. Accordingly, the liver
mass and hepatosomatic ratio were increased in all treated groups compared with CTRL
mice (Figure 2A).
Hepatomegaly was caused by a combination of hypertrophy and hyperplasia. Hepa-
tocytes of livers from animals of all WD-fed groups were almost twice enlarged compared
to CTRLs, as shown by phalloidin staining (Figure 2B). At the same time, Ki-67 staining re-
vealed mild but significantly higher cellular proliferation in all treated groups (Figure 2C).
Evaluation of histologic sections, by an experienced pathologist, revealed significant
hepatic steatosis in 30–80% hepatocytes of WD-fed animals. The cellular content was a
mixture of micro- and macrovesicular vacuoles, mainly located in the periportal regions
(Figure 2D, Supplementary Figure S2A). These vacuoles were confirmed to contain lipids
using Oil Red O (ORO) staining in liver cryosections (Figure 2E).
3.3. WD Feeding Induced Lipidome Alterations in Murine Livers
Next, a quantitative lipidomic analysis was performed in order to identify lipids
discriminating the pathological statuses of the liver. A lipidomic approach was taken to
quantify the major lipid classes.
Lipids were extracted from the liver tissue and further separated by Thin Layer
Chromatography (TLC). Total hepatic Triglyceride (TG) content was markedly increased
in all mice fed with WD compared with CTRL group (Figure 3A). However, the level of
Diglycerides (DG) was significantly increased only in mice fed with HP-WD and HP-Trans-
WD (Figure 3B). Importantly, hepatic Free Cholesterol (FC) levels significantly increased in
both groups fed with a HP diet (Figure 3C). The total Phosphatidylcholine (PC) content was
decreased (Figure 3D, left panel), whilst Phosphatidylethanolamine (PE) levels significantly
increased (Figure 3D, middle panel) and the PC/PE ratio decreased only in mice fed with a
transfat diet (Figure 3D, right panel). A trend towards decreased Phosphatidylserine (PS)
levels was found in the HP-Trans-WD group (Figure 3E).
3.4. WD Altered the Balance between Fat Storage and Oxidation in the Liver
Subsequently, we assessed the effects of all three types of WD on major molecular
mechanisms that regulate lipid metabolism in the liver. Consistently with previous stud-
ies [20], the excessive lipid load in all treated groups induced the expression of Pparγ,
early induced lipogenic transcription factor mediating an adipogenic transformation of
hepatocytes (Figure 4A, left panel).
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Figure 3. Hepatic lipidomic analysis in mice treated with WD and corresponding controls. Distribu-
tion of lipid classes within hepatic lipids (µmol/g of tissue): (A) Triglycerides (TG). (B) Diglycerides
(DG). (C) Free cholesterol (FC). (D) Hepatic hospholi ids Left: Phosphatidylcholine (PC). Mid-
dle: Phosphatidylethanolamine (PE). Right: PC/PE ratio. (E) Phosphatidylserine ( ) ).
* for p < 0.05, ** p < 0.01, *** p < 0.001; **** p < 0.0001.
We also found strong increase of Scd1 mRNA expression n all treated animals
(Figure 4A, right panel). Scd1 desaturase converts saturated FA to monounsaturated
FA [21], the major substrate for TG in the liver [22]. Hence, the substantial increase
in Scd1 expression was mainly induced by the excessive dietary fat, as mRNA of main
regulators of de novo lipogenesis Acc and Srebp1 were not increase after feeding with
WDs (Figure 4B). Furthermore, FASN protein expression was remarkably suppressed in
HP-Trans-WD group (Figure 4C).
Increased lipid load in the liver resulted in enhanced lipid oxidation only in LP-WD,
as observed by raised Acox and CPT-1c expression levels. In sharp contrast, the application
of both diets with high levels of PA seems to not induce the transcription of genes and
proteins for an adequate lipid oxidation (Figure 4D,E).
Finally, decreased Apob levels may indicate the impairment in Very Low Density
Lipoprotein (VLDL) secretion in HP-Trans-WD (Figure 4F).
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Figure 4. Changes in lipid metabolism in mice fed with WD. (A) Pparγ, Scd1, (B) Acc, Srebp1 mRNA
relative expression to GAPDH after 14 weeks on WD (n = 4–6). (C) FASN western blot using HSC-70
as a loading control. Ratio: normalization of FASN expression by densitometry. (D) Respective Acox
mRNA expression relative to Gapdh (n = 4–6). (E) CPT-1c WB using GAPDH as loading control.
Quantification of Western blot was performed by densitometry using Image J software. (F) Apob
mRNA expression relative to Gapdh (n = 4–6). * for p < 0.05, ** p < 0.01, *** p < 0.001.
3.5. WD with High Levels of PA and Trans Fat Increased the Risk of MAFLD-Associated Hepatitis
and Fibrosis
Excessive lipid a cumulation drives to cell death and inflammation in the liver [23].
Plasma levels of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST),
important clinical markers of hepatoce lular injury were significantly elevated in animals
fed ith - (Figure 5A). Thus, the detection of hepatic cell death in situ reveal d
significantly higher numbers of TUNEL positive cells in HP-WD and HP-Trans-WD fed
livers in comparison with LP-WD-fed animals and the controls (Figure 5B).
All WD treated groups sho ed an i r se lation f 80 positive liver
macrophages, as a se sed by Immunofluorescence (IF) staining (Figure 5C). A d tionally,
the mRNA expression of Tnf-α was significantly increased only in mice fed either with a
HP-WD or a HP-Trans-WD (Supplementary Figure S3A).
Cell death, inflammation and TNF-α overproduction induces the activation of Hepatic
Stellate Cells (HSCs) in the liver [24]. Consistently, significant expression of α-Smooth
Muscle Actin (α-SMA), a marker of HSCs activation, was detected by Immunohistochem-
istry (IHC) staining in both groups treated with HP-WD and HP-Trans-WD (Figure 5D).
Activated HSCs are the major source of Extracellular Matrix (ECM) during progression
of fibrosis [2]. Hence, Sirius Red (SR) staining clearly demonstrated that feeding with
HP-WD and HP-Trans-WD induced collagen expression in the liver (Figure 5E, Sup-
plementary Figure S3B). These findings were additionally confirmed by IF staining for
Collagen I (Figure 5F).
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3.6. The Withdrawal ofWD, Reversed MAFLD in All Treated Groups Independently of the
Diet Composition
Lastly, we investigated whether WD withdrawal could ameliorate MS and MAFLD-
related liver phenotype. The restoration of a chow diet feeding regimen for 20 days was
performed after 14 weeks of WD in all treated groups, while CTRL group was maintained
on chow diet for 17 weeks in total (Figure 6A). The switch from all different WDs to chow
feeding diet, induced a decrease in body weight (Figure 6B, Supplementary Figure S4A)
and significantly reduced hepatomegaly (Figure 6C, Supplementary Figure S4B), compared
with the corresponding 14 weeks feeding period of the three different types of WDs that has
been used, achieving similar levels of the CTRL group. The plasma levels of transaminases
and cholesterol progressively decreased over the duration of withdrawal in all treated
groups, and eventually reached almost the same level as in the CTRL animals (Figure 6D).
Importantly, WD withdrawal normalized impaired glucose intolerance in mice fed with
HP-Trans-WD (Figure 6E,F).
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Figure 6. Effects of WD withdrawal on MS. (A) Mice were fed for 14 weeks with WD followed
by 3 weeks of withdrawing. Effects of WD withdrawal: (B) Body and (C) Liver weight (n = 5–6).
(D) AST, ALT, Cholesterol in serum after 12 h of fasting (n = 3–5). (E) Basal glucose levels in blood
after 12 h of fasting. (F) Left: GTT curve after the period of withdrawal. Right: Area under the curve
GTT (arbitrary units) (n = 3–6).
In light of these metabolic improvements, pathological changes in the liver were
explored next. All WD withdrawal groups, showed significant improvement in hepato-
cellular morphology (Figure 7A) and attenuated hepatic steatosis with improved hepatic
TG content (Figure 7B,C). Moreover, even after 3 weeks of diet withdrawal, we observed
low-grade level of infiltration in both groups treated with high PA (Figure 7D). However,
the withdrawal was capable to revert fibrotic changes in all treated groups (Figure 7E).
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4. Discussion
Over the past two decades, some light has been shed on a number of aspects of MAFLD
pathogenesis and the complex relationships between liver steatosis, obesity and modifiable
risk factors such as food habits and sedentary lifestyle. Despite the increase in knowledge,
there is still no universally approved medical treatment for MAFLD patients [4]. The
current body of research suggests that the best way to prevent MAFLD is the combination
of a balanced diet with regular exercise to achieve a healthy weight. In contrast, excessiv
fat co sumption is strongly related with ccumulation of fat in t e liver. However, the
quality of fat might be as imp rtant as the quantity for MAFLD progression. Although the
effects of sp cific types of dietary fat on cardiovascular diseases have been m re or less
widely studied, there hav been only a limited number of investigations examining the
effects sp cifically on MAFLD in this r gard. Consequently, it is critical to investigate the
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effects of transfat and HP oils as possible triggers to the development of MAFLD, since the
consumption of ultra-processed foods, rich in both oils, is increasing worldwide.
Therefore, the aim of the present study was to investigate the effects of three differ-
ent WDs on the liver and the pathophysiological modulation that these diets perpetrate
as a mechanism to develop MAFLD. The consumption of all types of WDs rich in fat,
fructose and cholesterol for 14 weeks predisposed mice to the development of obesity, hep-
atomegaly, hepatic cell death and steatosis. Even LP-WD promoted obesity, hepatomegaly
and significant liver fat accumulation, with modulation of FA metabolism. Thus, only
HP-WD and HP-Trans-WD induced hypercholesterolemia and immune cell infiltration re-
sembling the pattern of Nonalcoholic Steatohepatitis (NASH). Moreover, only mice treated
with HP-WD and HP-Trans-WD developed significant liver fibrosis, an important hepatic
feature of MAFLD that is usually observed in patients with persistent necroinflammatory
changes [25] (Supplementary Figure S5).
Our observations are in line with previously published murine models fed with a high
fat diet (HFD) containing transfats—mice receiving American Lifestyle-Induced Obesity
Syndrome (ALIOS) diet [26]. ALIOS mice became obese and developed severe hepatic
steatosis with associated necroinflammatory changes. Plasma ALT levels increased, as liver
TNF-α and procollagen mRNA, indicating an inflammatory and profibrogenic response to
injury [25]. Feeding with a high-fructose medium-chain-transfat diet in another study was
also associated with obesity, increased hepatic oxidative stress and a steatohepatitis-like
phenotype with significant fibrosis [27].
The mechanisms of hepatic steatosis caused by transfats are the subject of considerable
debate. We examined mRNA expression of key lipid metabolic genes involved in FA
uptake, export and oxidation. Our data showed that the diet rich in transfat promotes
hepatic lipid accumulation by more than one mechanism. We found that HP-Trans-WD
in the liver reduced expression of Apob (hepatic TG secretion) and Acox (FA β-oxidation).
Both decreased FA oxidation and secretion are not able to offset the diet-induced increase
in intrahepatic lipid and together contribute to the diet-induced fatty liver and hepatic
accumulation of fat.
Consistently, it has been demonstrated in vitro [28,29], as well as in human studies [30],
that Trans FAs alter secretion and size of Apo-B100 containing particles produced by hep-
atic parenchymal cells and reduce the expression of FA Oxidation (FAO) enzymes [31].
In line with these observations, an increase of SCD1 activity in HP-Trans-WD was pre-
viously reported in obese subjects and associated with lower FA oxidation and higher
fat storage [21].
Interestingly, we found that feeding with HP-Trans-WD did not increase the expres-
sion of key genes of de novo lipogenesis, but in fact FASN expression was profoundly
suppressed. This appears paradoxical because FASN suppression markedly improves
steatosis in other experimental models of fatty liver, and FASN antagonists are under
development as plausible treatments for hepatic steatosis [32]. Therefore, it seems that
in HP-Trans-WD fed animals, FASN suppression is likely a compensatory mechanism
designed to reduce lipid synthesis under conditions in which lipid oxidation is reduced
and TG export is inactive. Moreover, FASN expression is impaired by hepatic inflammation
in experimental models characterized by severe hepatocellular damage and inflammation,
as well as in patients with steatohepatitis [33]. Consistently, mice fed with HP-Trans-WD
showed high levels of plasma markers of liver injury and significant inflammation in liver
tissue, accompanied by increased Tnf-α expression. Concomitant with our observation,
recent human studies showed that Trans FAs modulate human macrophage response,
increasing the production of TNF-α [34].
Lipidomic analysis revealed a marked step from DG to TG (precursor/product) in
HP-Trans-WD. These findings are highly consistent with human lipidomic MAFLD data
published by A.J. Sanyal’s group [35]. Moreover, knockdown of Diacylglycerol Acyl
Transferase (DGAT) ameliorates the fatty liver in the ob/ob mouse [36], suggesting that
DGAT plays an important role in the development of hepatic steatosis in mice fed HP-
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Trans-WD. Several publications also supported the link between altered DG levels and
insulin resistance [37].
DG are derived from lipogenesis and membrane phospholipids (PL). The lower
level of de novo lipogenesis and the parallel decrease in PC suggest that the membrane
PC may definitely contribute to the observed increase in DG in HP-Trans-WD mice in
the current study [34]. Indeed, PC is one of the most abundant PL in mammals and a
major component of cellular membrane lipids. Moreover, PC levels were reported to
be decreased in the liver samples of patients with MAFLD [35,38]. In hepatocytes, up
to 30% of PC comes from the conversion of Phosphatidylethanolamine (PE) to PC by
Phosphatidylethanolamine N-Methyltransferase (PEMT). Hence, the significant decrease of
the hepatic PC/PE ratio was previously observed in MAFLD patients [39]. Additionally, a
loss-of-function polymorphism in the PEMT gene seems to be associated with susceptibility
in MAFLD [39].
Furthermore, PC is the only phospholipid molecule that is known to regulate the
assembly and secretion of lipoproteins. It has been found that low hepatic PC levels due to
its synthesis disruption impair the VLDL secretion, and significantly decrease the levels
of circulating VLDL lipoproteins and result in hepatic accumulation of TG [40], which is
absolutely in line with low Apo-B100 gene expression in HP-Trans-WD.
Additionally, a low PC/PE ratio possibly leads to a rearrangement of outer monolayer,
loss of membrane integrity and increased permeability to pro-inflammatory molecules
such as cytokines, initiating the inflammation in HP-Trans-WD mice [41].
Glycerophospholipids are another component of cellular membrane associated with
cellular signaling and cellular apoptosis. Decreased levels of PS and PI were previously
reported in liver biopsy samples of patients with NASH [38].
Another striking observation was the increase in FC in mice fed HP-Trans-WD. FC is
well-known to be highly cytotoxic [42]. FC accumulation leads to liver injury through the
activation of signaling pathways in Kupffer Cells (KCs), HSCs and hepatocytes, promoting
inflammation and fibrogenesis [43]. Accordingly, we found significant hepatic infiltration
of F4/80 positive cells as well as HSC activation in the HP-Trans-WD group. Concomitantly,
Trans FA also increases the cellular accumulation and the secretion of free cholesterol by
hepatocytes in vitro [30,40].
Notably, we found that only HP-Trans-WD induced a significantly impaired glucose
tolerance after 14 weeks of feeding. Actually, transfats already have attracted critical
attention as a potential modifiable risk factor for T2DM in several previous studies. Diet
enriched in transfat intake has been associated with diabetes, insulin sensitivity and
systemic inflammation [44,45]. Animal studies demonstrated that a high transfat diet
causes weight gain and impaired insulin sensitivity in mice and monkeys [46,47].
Overall, our findings raise a red flag on the food high in transfats because of the
harmful effects on liver and metabolism in general. However, the proposed industrial
substitute—palm oil does not seem to be a good alternative either, mainly because of high
saturated FA, especially PA (C16:0 ≈ 44%). PA treatment has been known to induce inflam-
mation and cellular injury in various tissues. For example, Chen et al. showed that for each
kilogram of palm oil consumed annually per capita, the mortality due to ischemic cardiomy-
opathy increases to the equivalent of 68 for 100,000 deaths in developed countries [48].
The effects of saturated PA on the liver are another pressing issue [8,16]. Boland et al.
showed that the substitution of transfat with palm oil (GAN diet) resulted in maintained
NASH phenotype in both ob/ob and C57BL/6J mice [49]. In our study, we found that
animals fed with HP-WD develop obesity, hepatomegaly, steatosis, inflammatory cells
infiltration in the liver and fibrosis as HP-Trans-WD. The changes in the lipid metabolism
and lipidomic were also very similar between both groups: high Scd and Pparγ mRNA
expression levels in combination with low FA oxidation (CPT1, Acox), leading altogether
to significant fat accumulation in the liver. Moreover, the levels of TG, DG and FC were
similarly increased in HP-WD.
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The main difference between groups was that HP-WD feeding was not associated with
glucose intolerance and did not prompt the increase of transaminases as HP-Trans-WD.
In addition, the hepatic, metabolic and lipidomic changes were much more pronounced
in HP-WD compared with LP-WD fed animals. In accordance, a previous in vitro study
showed that saturated PA fatty acids induce hepatocyte lipoapoptosis, and it is more toxic
than with unsaturated fatty acids [50].
Lifestyle modifications including diet, exercise and weight loss have been found to be
effective in controlling MAFLD. Indeed, we found that WD withdrawal for only 3 weeks
resulted in significant improvement in several features of MS and MAFLD, and in general
was very efficient in returning most of the analyzed parameters to control-like levels.
The withdrawal from all types of WDs promoted lower body mass; decreased visceral
fat accumulation; remarkably improved steatosis, serum transaminases, cholesterol and
hepatic TG content; and attenuated hepatic fibrosis. Importantly, it also normalized glucose
tolerance in HP-Trans-WD. However, the specific lipid composition of the diet seems to
also be important in this setting. Liver inflammation in HP and HP-Trans-WD as seen
post-withdrawal, is not fully reversible. This, of course, raises concerns, pondering the
frequent cycling of diet and weight in the population with obesity.
Mouse models have been extensively used in many mechanistic studies of MAFLD
pathogenesis. In spite of this, the natural rodent diet is not fatty-acid-based, limiting the
extrapolation of results to humans. Moreover, mice exhibit significant differences in lipid
metabolism versus humans. For example, mice carry most of the plasma cholesterol in
HDL, while humans carry much of it in LDL [51]. It is still reasonable to assume that many
of the FA harmful effects for mice may also carry over to humans, both in terms of MS and
MAFLD. Thus, careful validation and functional comparisons of lipidomic profiles must
still be performed.
In summary, dietary recommendations to prevent and manage MAFLD should focus
not only on quantity but also quality of the diet. Our study clearly demonstrated that
modifying types of fat in the diet can lower risk of MAFLD progression and improve
features of MS. Yet, it is very important to understand that “transfat free” and/or “palm oil
free” labeling should not indulge people in buying high fat or processed food.
Altogether, this study provides important information on the role of different types of
fat for development and progression of MAFLD and could be used to inform policy makers
discussing the new European Union (EU) regulations to promote better food environments.
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